Combining Stem-Cell and Gene-Therapy Techniques to Tackle a Deadly Blood Disease
Researchers to discuss their stimulus-funded project at Boston conference
BOSTON, Oct. 22 /PRNewswire-USNewswire/ — The National Institutes of Health has awarded a three-year, $3.9 million grant to Children’s Hospital Boston researchers and their colleagues to develop a therapy to treat Fanconi anemia, a fatal genetic blood disease.
The researchers will investigate new ways to create induced pluripotent stem (iPS) cells from a patient’s skin or other tissue and transform them into genetically repaired hematopoietic stem cells that can make normal blood cells.
Fanconi anemia is characterized by progressive bone marrow failure, multiple congenital anomalies and a predisposition to cancer. Somehow, a defect in DNA repair causes progressive blood stem cell loss, usually resulting in death by age 20. Although the rare syndrome could potentially be treated with gene therapy, since it usually results from a single genetic mutation, the same DNA repair defect has thwarted gene therapy efforts to date. The team will push to understand the barriers to genetic correction of Fanconi anemia in mice, hoping their findings will translate to patients.
The research project is a collaboration among three members of Dana-Farber/Children’s Hospital Cancer Center: David Williams, MD, chief of Hematology/Oncology and director of Translational Research, George Daley, MD, Ph.D., director of Stem Cell Transplantation, and Alan D’Andrea, MD, chief of research in Radiation Oncology.
Two of the co-principal investigators will be discussing their efforts in Boston this weekend at the Congress of the International Society of Paediatric Oncology, the world’s largest pediatric oncology meeting. http://www.siopboston2010.com/
- On Friday, Oct. 22, 10:30-noon (Ballroom A), Williams will give a talk titled “Somatic Cell Reprogramming to Facilitate Genetic Correction in Fanconi Anemia” in a session on gene therapy and pediatric oncology. Williams, who completed an early study in children with Fanconi anemia to try to genetically correct endogenous blood stem cells, will discuss how clinical trials have defined a new research focus. “At the end of three years, one hope would be, in the mouse system, to generate corrected iPS cells and be able to differentiate them into corrected blood stem cells,” Williams says.
- On Sunday, Oct. 24, 3-3:30 p.m. (Auditorium), Daley will give a keynote talk titled “Modeling Bone Marrow Failure Syndromes with Induced Pluripotent Stem Cells.” Daley plans to address some of the limitations of reprogramming Fanconi anemia cells. “The grant is aimed at defining precisely what mechanism is lacking in Fanconi cells that is required for efficient reprogramming,” Daley says. “We believe the DNA repair defects of Fanconi cells are a problem–because the reprogramming technique may stress the DNA repair response and make them relatively resistant to reprogramming. With improved methods, we should achieve reprogramming of Fanconi cells too.”
The grant combines the efforts of three leading experts in the field. Their three projects are connected by common goals: To better understand the reprogramming technology and DNA repair pathways involved in Fanconi anemia cells first in mice, and then to leverage those insights for rapid development of new therapeutic approaches for translation to patients.
Williams’ group will concentrate on reprogramming patient-specific cells, using state-of-the-art methods to genetically correct these cells, and transforming them into functional hematopoietic stem cells for transplant. Daley’s lab will probe how defects in DNA double-strand break repair affects reprogramming of iPS cells. D’Andrea’s team will concentrate on the details of how the hematopoietic stem cell defect generates bone marrow failure and test new potentially therapeutic small molecules.
The Fanconi anemia grant marked Children’s Hospital final research award from the 2009 American Recovery and Reinvestment Act, the biggest boost in federal research funding in U.S. history. The stimulus funding infused hospital labs and clinics with about $55 million in direct support of more than 100 projects.
Dana-Farber/Children’s Hospital Cancer Center is a top referral center for children with Fanconi anemia and is hosting the international oncology meeting at the John B. Hynes Veterans Memorial Convention Center.
To learn more about the International Society of Paediatric Oncology (SIOP) or to register for the press room, contact Teresa Herbert, Senior Media Relations Specialist, Dana-Farber Cancer Institute firstname.lastname@example.org; 617-632-4090.
Children’s Hospital Boston is home to the world’s largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including nine members of the National Academy of Sciences, 12 members of the Institute of Medicine and 13 members of the Howard Hughes Medical Institute comprise Children’s research community. Founded as a 20-bed hospital for children, Children’s Hospital Boston today is a 392-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children’s also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital and its research visit: www.childrenshospital.org/newsroom.
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Children’s Hospital Boston as Dana-Farber/Children’s Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.
CONTACT: Bess Andrews Children's Hospital Boston 617-919-3103 email@example.com
SOURCE Children’s Hospital Boston